Internal Medicine, Hematology & Oncology · Belleville, NJ
NPI
1053397224
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
1 Clara Maass Dr Ste 200
Belleville, NJ, 07109
Phone (973) 751-8880
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
103,154 services
Medicare patients, 2024
524
Average age 75
Drug cost, 2024
$3.5M
1,405 prescriptions
Company payments, 2025
$2,158
From 37 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Hemalatha Vasireddy was code J1439 (injection, ferric carboxymaltose, 1 mg), 26,250 times for 12 patients. In total Hemalatha Vasireddy billed 103,154 services in 99 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 26,250 | 12 | $0.87 | $23K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,033 | 14 | $0.09 | $92.38 |
| 36415 Venipuncture Blood Collection | Office | 963 | 258 | $8.65 | $8,330 |
| 85025 Blood Count | Office | 945 | 258 | $7.58 | $7,160 |
| 99232 Hospital E&M - Subsequent | Facility | 821 | 238 | $65.77 | $54K |
| 99214 Office E&M - Established | Office | 612 | 221 | $99.89 | $61K |
| 96413 Chemotherapy Administration | Office | 227 | 26 | $116.24 | $26K |
| 96372 Injection Administration | Office | 199 | 31 | $12.28 | $2,443 |
| 96375 Injection Administration | Office | 186 | 19 | $13.28 | $2,470 |
| 96367 Intravenous Infusion, Hydration | Office | 180 | 37 | $24.88 | $4,479 |
| 99222 Hospital E&M - Initial | Facility | 171 | 150 | $103.27 | $18K |
| 96365 Intravenous Infusion, Hydration | Office | 143 | 37 | $54.82 | $7,839 |
| 99291 Critical Care E&M | Facility | 132 | 43 | $173.20 | $23K |
| 96361 Intravenous Infusion, Hydration | Office | 123 | 12 | $11.03 | $1,356 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 104 | 28 | $0.64 | $66.11 |
By year: 2022 $1.1M for 88,121 services; 2023 $1.4M for 114,210 services; 2024 $1.2M for 103,154 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 963 | 258 | $8.65 | $8,330 |
| 85025 Blood Count | 945 | 258 | $7.58 | $7,160 |
Medicare prescription drug claims, 2024
In 2024, the drug Hemalatha Vasireddy prescribed most often to Medicare patients was Anastrozole, with 205 prescriptions and refills. In total Hemalatha Vasireddy wrote 1,405 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 205 | 574 | 69 | $4,501 |
| Keytruda Pembrolizumab | 72 | 72 | Under 11 | $830K |
| Eliquis Apixaban | 49 | 80 | 20 | $46K |
| Palonosetron Hcl Generic | 35 | 35 | Under 11 | $2,671 |
| Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosp/Pf | 31 | 31 | Under 11 | $271 |
| Fosaprepitant Dimeglumine Generic | 31 | 31 | Under 11 | $3,842 |
| Sandostatin Lar Depot Octreotide Acetate,mi-Spheres | 27 | 27 | Under 11 | $156K |
| Procrit Epoetin Alfa | 27 | 27 | 14 | $65K |
| Dexamethasone Generic | 25 | 26 | Under 11 | $316 |
| Xarelto Rivaroxaban | 24 | 48 | Under 11 | $25K |
| Gabapentin Generic | 24 | 28 | Under 11 | $260 |
| Megestrol Acetate Generic | 24 | 31 | 14 | $2,565 |
| Xgeva Denosumab | 23 | 23 | Under 11 | $73K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 22 | 22 | 15 | $249 |
| Tramadol Hcl Generic | 22 | 22 | 17 | $133 |
Brand drugs: - claims; generic drugs: 905 claims; opioid claims: 65.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Hemalatha Vasireddy $2,158 ($2,158 in general payments such as food, travel and fees) from 37 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $322.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 17 | $322 |
| E.R. Squibb & Sons, L.L.C. BMY | 14 | $225 |
| Incyte Corporation INCY | 4 | $159 |
| Daiichi Sankyo Inc. 4568.T | 9 | $154 |
| Seagen Inc. PFE | 1 | $92.99 |
| BeOne Medicines USA, Inc. ONC | 4 | $84.6 |
| GlaxoSmithKline, LLC. GSK | 4 | $79.05 |
| Merck Sharp & Dohme LLC MRK | 5 | $78.91 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $75.28 |
| Karyopharm Therapeutics Inc. KPTI | 4 | $65.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.